Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Kisspeptin-10
Also known as: KP10, KP-10, Metastin 45-54
A single IV dose roughly triples luteinizing hormone within 30 minutes in healthy men [1]. Kisspeptin-10 is the smallest active fragment of kisspeptin, the peptide that tells your hypothalamus to turn on the reproductive hormone cascade. It binds KISS1R on GnRH neurons, triggering a pulsatile release of LH and FSH from the pituitary. The catch: a plasma half-life around 4 minutes after IV dosing, and documented receptor tachyphylaxis with continuous or twice-daily exposure. IVF trials have tested the longer form, kisspeptin-54, as an egg-maturation trigger. The bodybuilding and TRT recovery community uses it to restart endogenous testosterone production.
What Is Kisspeptin-10?
Within 30 minutes of an IV dose, serum LH climbs sharply in healthy men. That speed is what makes kisspeptin-10 (KP10, amino acids 112 to 121 of the KISS1 gene product, MW ~1,302 Da) unusual among reproductive peptides. It sits at the very top of the HPG axis, binding the KISS1R (GPR54) receptor on GnRH neurons to trigger downstream gonadotropin release.
George and colleagues (J Clin Endocrinol Metab 2011)[1] gave healthy men IV boluses of kisspeptin-10. LH rose most at 1 mcg/kg, from 4.1 to 12.4 IU/L at 30 minutes, and less at 3 mcg/kg. Infusions lasting up to 22.5 hours raised testosterone and increased LH pulse frequency and size. A separate study [2] demonstrated sexual dimorphism in the response; women responded in the preovulatory phase but showed no gonadotropin change in the follicular phase. George and colleagues [3] extended this to men with type 2 diabetes and hypogonadism, where kisspeptin-10 still produced an acute LH rise.
In practice, the community uses it primarily for two things: natural testosterone optimization and post-TRT HPTA restart. The typical protocol is 100 to 125 mcg subcutaneous nightly, cycled 30 days on and 30 days off. Forum presence is thin compared to BPC-157 or TB-500 but concentrated in specialist boards like ExcelMale.
The honest limitation: no large randomized controlled trial has tested kisspeptin-10 for therapeutic hypogonadism. Post-TRT recovery application is biologically plausible but formally unstudied. Frequent or continuous dosing causes desensitization: twice-daily kisspeptin-54 in women [4] and continuous kisspeptin-10 infusion in men [6]. The peptide itself degrades faster than almost anything else on the market, with an in vitro plasma half-life of roughly 55 seconds.
How Kisspeptin-10 Works
Kisspeptin-10 is the minimal bioactive fragment of the KISS1 gene product. It binds with high affinity to KISS1R (GPR54), a G-protein coupled receptor sitting on GnRH neurons in the arcuate and anteroventral periventricular nuclei of the hypothalamus.
Receptor activation triggers Gq/11 signaling. Intracellular calcium rises, protein kinase C activates, and the GnRH neuron depolarizes. The result is pulsatile GnRH secretion into the hypophyseal portal system at the median eminence, a region that lacks a complete blood-brain barrier. GnRH then hits gonadotroph cells in the anterior pituitary, releasing both LH and FSH.
The LH pulse following an IV kisspeptin-10 bolus peaks at about 30 minutes [1] and returns to baseline within roughly 3 hours. In men, that LH spike drives Leydig cell testosterone production. In women, the magnitude depends on menstrual cycle phase; preovulatory timing produces the largest response.
One detail that matters for long-term protocols: kisspeptin neurons also integrate metabolic signals from leptin, insulin, and ghrelin, plus photoperiod cues. They function as a gatekeeping node that couples energy status to reproductive output. Repeated or continuous exposure leads to GnRH neuron desensitization and reduced gonadotropin output. That property is actually being explored for endometriosis and precocious puberty, where suppression of the reproductive axis is the goal.
Kisspeptin-10 Benefits
- Kisspeptin-10 benefits center on upstream HPG axis stimulation and the body's own hormone production.
- Stimulates LH release fast. In healthy men, an IV bolus of 1 mcg/kg raised LH from 4.1 to 12.4 IU/L at 30 minutes [1].
- Raises testosterone through the endogenous pathway. Exogenous testosterone suppresses the hypothalamus and HCG bypasses it; kisspeptin-10 acts above both, which is why HPTA restart protocols use it. Continuous exposure can blunt this pathway (see Side Effects).
- Raised LH in 5 men with type 2 diabetes and low testosterone (George et al.)[3]. An 11-hour infusion in 4 of them lifted testosterone from 8.5 to 11.4 nmol/L.
- Studied as an IVF oocyte maturation trigger, but only as kisspeptin-54. In 60 women at high OHSS risk, none developed moderate or severe OHSS [5]. KP10 shares the KISS1R mechanism but has no trigger data.
- A needle-free route is in testing, though with kisspeptin-54, not KP10. In a 2025 eBioMedicine trial [7], 12.8 nmol/kg intranasal kisspeptin-54 raised peak LH by a mean 4.4 IU/L in healthy men.
- Community users consistently report improved morning erections, mood, and energy starting around days 5 to 10 of daily subcutaneous dosing.
Kisspeptin-10: Science vs Community Consensus
KP10 stimulates LH and FSH release in healthy men, and in women only in the preovulatory phase, via KISS1R → GnRH → pituitary axis.
Read the evidence (key study, limitations)
Proof-of-concept in T2DM hypogonadism [3]. Blunted response in severe iHH patients. Tachyphylaxis is documented with twice-daily kisspeptin-54 [4] and continuous kisspeptin-10 infusion [6]. Intranasal kisspeptin-54 raised LH in a 2025 trial [7]; KP10 has no intranasal data. No FDA-approved therapeutic indication; FDA has listed KP10 in 503A Category 2 since Sept 29, 2023.
PMID 21632807: KP10 IV boluses raised LH in healthy men, most at 1 mcg/kg. Infusions up to 22.5 hours raised testosterone and LH pulse frequency and size (J Clin Endocrinol Metab 2011)
No large RCTs for therapeutic hypogonadism endpoints. Post-TRT recovery application is community-only, not formally studied. In one IV study, 3 mcg/kg raised LH less than 1 mcg/kg (PMID 21632807). No human study has measured subcutaneous bioavailability or tested once-daily injections (FDA 2024 review). In follicular-phase women, single subcutaneous injections raised plasma kisspeptin but did not change LH (PMID 21976724). iHH patients show blunted response vs. healthy controls.
Used primarily for post-TRT HPTA restart and natural testosterone optimization.
Read the reports (what users report 4, common issues 5)
Regarded as a clean LH stimulator that does not suppress endogenous production. Consistent complaints: variable individual response, short half-life requiring precise timing, and confusion with kisspeptin-54.
- Natural testosterone stimulation through the body's own HPG axis
- LH surge for PCT and fertility support
- Perceived cleaner response vs. synthetic GnRH agonists at pulsatile doses
- Anecdotal libido improvement consistent with testosterone rise over 2–4 weeks
- Very short half-life: inconsistent timing reduces efficacy
- Variable individual response; iHH patients respond poorly
- Kisspeptin-10 vs. kisspeptin-54 confusion causes dosing errors
- Expensive relative to gonadorelin or HCG for PCT
- Tachyphylaxis with continuous daily dosing if cycling not implemented
Science confirms strong acute LH stimulation and tachyphylaxis risk. Community application for post-TRT recovery is biologically plausible but not formally studied. No study has tested the community's injection doses. Tachyphylaxis is documented with twice-daily and continuous exposure; whether once-daily injections need cycling is untested.
Kisspeptin-10 Dosage Guide
The math on this one matters. A 5 mg vial reconstituted with 2 mL bacteriostatic water gives you 2,500 mcg per mL, or 25 mcg per unit on a U-100 insulin syringe. For a 100 mcg dose, you're pulling 4 units. For 125 mcg, pull 5 units.
Use BAC water specifically. Sterile water lacks the benzyl alcohol preservative, and given how fast kisspeptin-10 degrades, you want every stability advantage. Plan to use the reconstituted vial within 7 to 10 days, maybe 14 at the outside. Refrigerate immediately after mixing.
Timing matters more than usual here. Kisspeptin-10 clears the blood within minutes of an IV dose [2]; no study has reported a half-life for a subcutaneous dose. Most community protocols call for evening dosing, 60 to 90 minutes before bed, at the same time each day. Don't skip the day-7 LH blood draw (30 to 60 minutes post-injection). It tells you whether your vial is active and your receptors are responding.
Cycling Protocol
No weeks-long on/off cycle has been tested in people. Before a 2026 infusion trial, FDA's 2024 review found no kisspeptin-10 trial longer than a day. Community protocols run 4 weeks on and 4 off (or 30 days on and 30 off) as a precaution against desensitization. Monitor LH and testosterone to see whether your response holds.
Continuous kisspeptin exposure desensitizes the KISS1R (GPR54) pathway. Twice-daily kisspeptin-54 injections in women with hypothalamic amenorrhea cut the LH rise from 24.0 to 2.5 IU/L by the 14th injection day (PMID 19820030). With kisspeptin-10 in healthy men, the LH response to continuous infusion was gone by day 5 (PMID 42549827). It held for 12 days with daily 8-hour infusions. No trial has tested once-daily injections or a weeks-long on/off cycle. Community cycles of 4 weeks on and 4 off, or 5 days on and 2 off, are a precaution, not a tested regimen.
- Diminishing LH response vs. first week: confirm with 30-min post-injection blood draw
- Testosterone trending back toward baseline despite continued daily injections
- Reduced or absent morning erections that were noticeably improved in weeks 1–2
- Subjective sense of diminishing response without protocol changes
Or use the universal Peptide Calculator for any peptide.
Kisspeptin-10 Protocols by Goal
Expected: Community reports: improved morning erections, mood and energy from days 5–10, while some users notice no change. No trial has measured LH or testosterone after daily SC injections, so the day-7 and day-28 labs show whether you respond.
Monitor: LH at day 7 (30–60 min post-injection) and day 28; total testosterone at day 28
How to Use Kisspeptin-10
- 1Step 1
Gather supplies: 5 mg kisspeptin-10 vial, 2 mL bacteriostatic water, alcohol swabs, U-100 insulin syringe (28 to 31 gauge, 0.5 inch needle).
- 2Step 2
Reconstitute by injecting 2 mL BAC water slowly down the inside wall of the vial. Do not shake. Swirl gently until dissolved. This gives 2,500 mcg/mL (25 mcg per unit on a U-100 syringe).
- 3Calculate your dose
For 100 mcg, draw 4 units. For 125 mcg, draw 5 units. For 200 mcg, draw 8 units. For 300 mcg, draw 12 units.
- 4Clean the injection site with an alcohol swab
Preferred sites: abdominal fat (2 inches from the navel) or anterior thigh. Rotate sites daily.
- 5Step 5
Pinch the skin and insert the needle at a 45 to 90 degree angle. Inject slowly. Hold for 5 seconds before withdrawing.
- 6Step 6
Timing: inject in the evening, 60 to 90 minutes before bed, at the same time each day. A steady daily time keeps your day-7 LH check comparable from one cycle to the next.
- 7Step 7
Store the reconstituted vial refrigerated at 2 to 8 degrees Celsius. Use within 7 to 14 days. Do not freeze reconstituted peptide.
- 8Step 8
On day 7, get a blood draw for LH at 30 to 60 minutes post-injection to confirm your individual response. Total testosterone at day 14 and day 28 tracks the downstream effect.
Alternative Routes
Subcutaneous dosing keeps blood levels up longer than IV (in women, PMID 21976724), but no half-life or bioavailability has been measured (FDA 2024 review). The community dose of 100–200 mcg/day isn't based on any measured conversion.
Rotate sites (abdomen, anterior thigh). Use 28–31 gauge, 0.5-inch needle.
12.8 nmol/kg intranasal kisspeptin-54 raised mean peak LH by 4.4 IU/L in healthy men and in hypothalamic amenorrhea patients (PMID 40215751). No SC-to-intranasal conversion established; direct dose comparison not available.
First non-invasive kisspeptin route with confirmed LH stimulation in humans (kisspeptin-54). Requires specific nasal spray formulation (stable 60 days refrigerated in published protocol). Not achievable with standard peptide reconstitution. Monitor for commercial or compounding development.
IV bolus doses in clinical trials: 0.01–3.0 mcg/kg in men (PMID 21632807) and up to 10 nmol/kg in women (PMID 21976724). In men, 3 mcg/kg raised LH less than 1 mcg/kg (PMID 21632807). Provides immediate peak kinetics; extremely short duration (~4 min half-life).
Reserved for diagnostic testing and clinical research. Self-IV carries unacceptable infection and dosing-error risk.
Kisspeptin-10 Stacking Protocols
Works With
Sequential HPG axis coverage: KP10 stimulates hypothalamic GnRH neurons; gonadorelin (synthetic GnRH) stimulates pituitary gonadotrophs. Used in post-TRT restart for two-level axis stimulation simultaneously.
100 mcg KP10 + 100 mcg gonadorelin SC daily, same window or staggered 30 min apart
Three-level PCT stack: KP10 (hypothalamus) + HCG (direct Leydig cell stimulation bypassing hypothalamus and pituitary). Covers all three HPG axis levels. Community commonly pairs these during post-TRT recovery.
KP10 100–150 mcg SC daily + HCG 500–1000 IU SC 2–3×/week; monitor testosterone to avoid over-stimulation
Avoid
GnRH antagonists block pituitary GnRH receptors, abolishing the downstream LH response that KP10 depends on. Concurrent use renders kisspeptin-10 pharmacologically inert.
Do not combineContinuous GnRH agonist exposure causes pituitary desensitization. Concurrent KP10 will produce unpredictable and likely suppressed gonadotropin responses.
Do not combineNot dangerous to combine, but mechanistically redundant for libido purposes and from different pharmacological timescales. PT-141 gives rapid CNS arousal (minutes); KP10 provides slow hormonal axis effects (weeks). May cause additive nausea and flushing.
How much does Kisspeptin-10 cost?
Typical price
$4.50 to $6.07 per mg
Middle half of 82 US prices for 10 mg vials · read Oct 31
Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.
Kisspeptin-10 Side Effects
The most important safety concern with kisspeptin-10 is receptor desensitization. A study by Jayasena and colleagues [4] documented tachyphylaxis with twice-daily kisspeptin-54 injections in women with hypothalamic amenorrhea. LH response diminished with uninterrupted dosing. Kisspeptin-10 shares the same KISS1R receptor and is subject to the same mechanism. A 2026 randomized study in healthy men saw that pattern with kisspeptin-10 itself [6]. After 5 days of continuous subcutaneous infusion (4 men), LH and FSH were no higher than placebo, though testosterone stayed raised. Daily 8-hour infusions with 16-hour breaks (7 men) kept LH raised for 12 days. This is not a mild inconvenience; under continuous exposure, the peptide can stop raising LH. No trial has tested whether a weeks-long on/off cycle prevents it.
The second concern is specific to product quality. Kisspeptin-10 has an in vitro plasma half-life of approximately 55 seconds, destroyed by matrix metalloproteinases. It is one of the most degradation-prone peptides available. A vial shipped without cold-chain integrity, reconstituted too early, or stored beyond 2 weeks may contain little to no active peptide. FDA has listed kisspeptin-10 in 503A Category 2 since September 29, 2023. FDA says Category 2 substances "may present significant safety risks"; for kisspeptin-10 it cites possible immunogenicity and limited safety data. Current supply comes from research-chemical products with variable quality control.
Published clinical side effects from controlled studies include headache, nausea, and hot flushes. These appear dose-related and are reported at higher IV doses. At community subcutaneous doses of 100 to 200 mcg daily, user reports of adverse effects are sparse. The community sample size is low, concentrated on specialist boards rather than mainstream peptide forums.
One interaction worth flagging: opioid analgesics suppress kisspeptin neuron activity. Chronic opioid use may reduce responsiveness to kisspeptin-10, and opioid-induced hypogonadism already impairs the HPG axis at multiple levels.
For hormone-sensitive cancers (breast, prostate, ovarian), acute gonadotropin stimulation from kisspeptin-10 may temporarily spike sex steroid levels. This is a contraindication, not a theoretical concern.
Pregnancy is a clear contraindication. Kisspeptin stimulates gonadotropin release that could disrupt early pregnancy hormone balance. Safety in pregnant women has not been studied.
Anyone using kisspeptin-10 should stop and consult a physician if persistent headache or nausea develops, if no measurable LH response appears after 14 days of consistent dosing, or if symptoms suggest hormonal excess (gynecomastia, acne flares, mood instability).
Common Issues & Solutions
No measurable LH response after 14 days: Check blood draw timing. Community protocols draw at 30–60 min post-injection, though the subcutaneous LH peak hasn't been timed in men. Likely causes: severe HPG axis suppression (iHH patients respond poorly per published data), degraded peptide from storage failure, or inadequate injection technique. Confirm vial reconstituted in BAC water and stored refrigerated.
Loss of response after initial success: possible KISS1R desensitization (tachyphylaxis), documented with twice-daily kisspeptin-54 [4] and continuous kisspeptin-10 infusion [6]. Community practice is a full washout of about 4 weeks before restarting, or a 5 days on / 2 off weekly pattern. Neither has been tested.
No acute libido or erection effect: Expected: KP10 is not PT-141. It acts via the hormonal axis over 2–4 weeks via testosterone rise, not acute CNS arousal. Wrong tool for on-demand use.
Vial appears inactive / no response at first use: In vitro half-life of KP10 is ~55 seconds: one of the most degradation-prone peptides on the market. Causes: shipping without cold pack, reconstituted too early and stored too long (>2 weeks), or non-sterile water used. Replace the vial with one backed by a verified COA; use BAC water; inject within 7–10 days of reconstitution.
Kisspeptin-10 vs. kisspeptin-54 confusion causing over/underdosing: These are not interchangeable. KP54 half-life ~28 min IV vs. KP10 ~4 min; KP54 produces larger sustained LH pulse. Do not apply KP54 nmol/kg dose directly to KP10: equimolar dose of KP10 will produce a weaker, shorter LH pulse.
Ask AI about this page
Ask AI for a second opinion on Kisspeptin-10 dosing and side effects
Contraindications
- Pregnancy: kisspeptin stimulates gonadotropin release which could disrupt early pregnancy hormone balance; not studied for safety in pregnant women
- Hormone-sensitive cancers (breast, prostate, ovarian): acute gonadotropin stimulation may temporarily increase sex steroid levels
- Precocious puberty: exogenous kisspeptin could worsen premature activation of the HPG axis
- Children and adolescents: not studied for safety in pediatric populations outside diagnostic settings
- Known hypersensitivity to kisspeptin peptides or any excipients
- Severe hepatic or renal impairment: clearance kinetics have not been characterized in these populations
Drug Interactions
- GnRH agonists (leuprolide, goserelin): concurrent use may cause unpredictable gonadotropin responses; kisspeptin acts upstream of GnRH
- GnRH antagonists (cetrorelix, ganirelix): may blunt the LH response to kisspeptin by blocking pituitary GnRH receptors
- Testosterone replacement therapy: exogenous testosterone suppresses endogenous LH via negative feedback, potentially reducing kisspeptin effectiveness
- Oral contraceptives and estrogen/progesterone therapy: steroid feedback on the hypothalamus and pituitary may alter kisspeptin-induced gonadotropin release
- Clomiphene citrate: both act to increase gonadotropin output; combined effects have not been studied
- Opioid analgesics: endogenous opioids suppress kisspeptin neuron activity; chronic opioid use may reduce kisspeptin responsiveness
- Continuous GnRH agonist exposure causes pituitary desensitization. Concurrent KP10 will produce unpredictable and likely suppressed gonadotropin responses.
Product Quality
KP10 is one of the most degradation-prone research peptides: in vitro plasma half-life ~55 seconds, enzymatically destroyed by matrix metalloproteinases. The research chemical market is thin: few brands, limited third-party HPLC/MS testing. No compounding pharmacy access (FDA 503A Category 2 since Sept 2023). Quality depends entirely on batch COA and cold-chain integrity.
- Lot-specific HPLC purity certificates ≥98% are the usual benchmark
- Store lyophilized vial refrigerated at 2–8°C; reconstituted peptide must stay refrigerated and be used within 7–14 days
- Use bacteriostatic water (0.9% benzyl alcohol) for reconstitution: extends stability vs. plain sterile water
- Do not freeze reconstituted KP10: freezing accelerates peptide bond hydrolysis
- Identity confirmation needs mass spectrometry (MS) verification, not UV absorbance alone
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Serum LH | 30–60 min post-injection at day 7 of protocol (timed draw) | No validated target for a subcutaneous injection. For reference, a 1 mcg/kg IV bolus raised LH from 4.1 to 12.4 IU/L at 30 minutes in healthy men (PMID 21632807). |
| Total testosterone | Fasted AM baseline, then day 14 and day 28 | Upward trend vs. baseline; absolute target depends on clinical context |
| FSH | Baseline and day 28 | Not listed |
| Estradiol (E2) | Baseline and day 28, especially during post-TRT restart with HCG co-administration | 20–40 pg/mL male reference range; adjust protocol if estradiol rises disproportionately to testosterone |
Confirms individual KISS1R responsiveness; no LH rise at all suggests iHH, axis suppression, or degraded peptide
Primary therapeutic endpoint for hypogonadism and post-TRT recovery protocols
Confirms full gonadotropin axis stimulation; FSH rise confirms pituitary is responding to GnRH output
Rising testosterone will aromatize; monitor for estrogen excess during HPG recovery, particularly when stacking with HCG
Kisspeptin-10 Before and After
After an IV dose, kisspeptin-10 is cleared within minutes (half-life about 4 minutes, PMID 21976724) and serum LH starts climbing. Subcutaneous timing hasn't been reported. No subjective effects are typically noticed.
After an IV dose in healthy men, LH peaks around 30 minutes (PMID 21632807). FSH also rises but with a smaller magnitude. A single IV dose did not raise testosterone consistently (PMID 21976724); multi-hour infusions did (PMID 21632807).
LH levels gradually return to baseline by approximately 3 hours. The acute hormonal cascade is complete.
No study has tested daily injections. LH and testosterone rose during a 22.5-hour IV infusion, and a 9-hour infusion made LH pulses more frequent (PMID 21632807). Daily 8-hour subcutaneous infusions kept LH raised for 12 days (PMID 42549827).
Tachyphylaxis may develop with continuous exposure. Pulsatile or intermittent dosing protocols may better maintain responsiveness. Testosterone and gonadotropin changes should be monitored by bloodwork.
What to Expect
Minutes 0 to 30: After IV dosing, kisspeptin-10 is cleared within minutes (half-life about 4 minutes)[2]. Subcutaneous timing hasn't been measured. Nothing feels different yet. Most users take the injection and go about their evening.
Minutes 30 to 90: After an IV dose in healthy men, LH hits its peak around 30 minutes. FSH rises too, though with a smaller magnitude. A single IV dose did not raise testosterone consistently in men [2]; multi-hour infusions did [1]. Some users report a subtle warmth or energy shift in this window. Honestly, that is likely psychosomatic or an early hormonal signal that is hard to separate from placebo.
Days 1 to 7 (repeated dosing): No study has tested daily injections, so the science here comes from infusions. Daily 8-hour subcutaneous infusions kept LH raised for 12 days [6]. Community reports point to improved morning erections, mood, and energy starting around days 5 to 10. Individual response is highly variable; some users notice nothing subjective at all. Occasional headache is the effect users mention most. FDA's 2024 review lists one adverse-event report at a community dose. A 17-year-old on 100 mcg daily for six weeks gained weight and had raised estrone, though FDA found the timing unclear.
Weeks 2 to 4: Community users treat this as the peak window, though no trial has run this long. Desensitization is the main risk; it's documented with twice-daily and continuous exposure, not yet with once-daily injections. Community users most commonly report improved libido, strength, and general well-being at weeks 3 to 4. Some users report diminishing returns when they skip breaks. Reduced LH response on blood draws is the first sign of KISS1R fatigue.
Weeks 4 and beyond (off cycle): How fast KISS1R sensitivity recovers during a washout hasn't been measured in people. Most users maintain testosterone gains for 2 to 4 weeks after stopping, then see a gradual taper. The community standard for long-term use is 30 days on, 30 days off, or 4 weeks on, 4 weeks off.
Detailed Timeline: Science vs Community
IV kisspeptin-10 is cleared within minutes (half-life about 4 min, PMID 21976724). Subcutaneous timing has not been measured. No subjective effects in this window.
No noticeable effects. Users take injection and continue normal activity.
After an IV dose in healthy men, LH peaks around 30 min (PMID 21632807). FSH rises with smaller magnitude. A single dose did not raise testosterone consistently (PMID 21976724).
Some users report subtle warmth or energy shift around this window: likely psychosomatic or early testosterone-adjacent.
No trial of daily injections. Daily 8-hour subcutaneous infusions kept LH raised for 12 days in healthy men (PMID 42549827).
Improved morning erections, mood, and energy beginning days 5–10. Individual response is highly variable; some users report no noticeable change.
No trial of daily injections this long. Tachyphylaxis is documented with twice-daily kisspeptin-54 by day 14 (PMID 19820030) and with continuous kisspeptin-10 infusion within 5 days (PMID 42549827).
Improved libido, strength, and well-being most commonly reported at 3–4 weeks. Diminishing returns begin if cycling not implemented.
Recovery of KISS1R sensitivity during a washout has not been measured in people.
Most users maintain testosterone gains for 2–4 weeks after stopping, then gradually taper. 30/30 or 4/4 cycling is community standard for long-term efficacy preservation.
Pharmacokinetics
Source: Plasma half-life of 3.8 minutes in men and 4.1 minutes in women after a 90-minute IV infusion (PMID 21976724). No subcutaneous half-life has been reported.
Pharmacokinetics: Active Dose Over Time
t½ = ~4 min (IV); not measured for SCDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Kisspeptin-10 Legal?
Kisspeptin-10 is classified as a research chemical in the United States. It has no FDA-approved therapeutic indication. FDA has listed kisspeptin-10 in 503A Category 2 since September 29, 2023. FDA says Category 2 substances "may present significant safety risks"; for kisspeptin-10 it cites possible immunogenicity and limited safety data. It was still there on FDA's page on October 6, 2026. FDA scheduled its Pharmacy Compounding Advisory Committee to discuss kisspeptin-10 on October 29, 2024 (Federal Register 2024-21241). No FDA rule adds it to the 503A bulks list.
Current supply is exclusively research-grade product labeled "research purposes only, not for human consumption." Quality varies widely. Lot-specific certificates of analysis with HPLC purity and mass spectrometry identity confirmation are the minimum standard for evaluating a batch.
The World Anti-Doping Agency (WADA) added kisspeptin and its agonist analogues to its Prohibited List in 2024 (S2.2.1, testosterone-stimulating peptides in males). For male athletes, that class is banned at all times, in and out of competition.
Clinical research continues internationally. Kisspeptin-54 (the full-length form) has more advanced clinical trial data, particularly for IVF applications. A 2025 trial gave kisspeptin-54 as a nasal spray and raised LH in humans [7]; kisspeptin-10 has no intranasal data.
This content is for informational and research purposes only. It does not constitute medical advice. Consult a qualified healthcare provider before using any research peptide.
Evidence grade: Phase 3 trial (Peptide Evidence Gap, October 2026)
Who Should Consider Kisspeptin-10
- Men with functional hypogonadotropic hypogonadism seeking natural testosterone stimulation
- Adults being evaluated for pubertal or hypothalamic reproductive disorders (diagnostic use)
- Researchers studying neuroendocrine control of reproduction
Related Peptides
What Changed for Kisspeptin-10
- Dosing
Corrected Oct 17, 2026: Kisspeptin-10's moderate and aggressive tiers are now 200 and 300 mcg; no trial tested daily injections, per FDA's 2024 briefing.
Before: Beginner 100, moderate 300, aggressive 400 mcg daily After: Beginner 100, moderate 200, aggressive 300 mcg daily
What this does not mean: No new study was published, and no dose is newly supported. The old 400 mcg tier sat above the page's own community ceiling of about 300 mcg a day. The tiers stay labeled speculative.
Source: FDA, Pharmacy Compounding Advisory Committee briefing document for kisspeptin-10, October 29, 2024: no published trial assessed the safety of kisspeptin-10 given chronically or on a fixed schedule for over one day (p. 22); no study reported subcutaneous Cmax or Tmax (p. 18) (opens in a new tab) · Saved copy
- Safety
Corrected Oct 17, 2026: Kisspeptin-10's side effects no longer say cycling keeps it working; no weeks-long cycle had been tested, per FDA's 2024 briefing.
Before: Desensitization "can render the peptide pharmacologically useless if cycling protocols are not followed" After: Under continuous exposure the peptide can stop raising LH; no trial has tested whether a weeks-long on/off cycle prevents it
What this does not mean: Desensitization is still documented with twice-daily kisspeptin-54 and continuous kisspeptin-10 infusion. Only the claim that an on/off cycle prevents it was removed.
Source: FDA, Pharmacy Compounding Advisory Committee briefing document for kisspeptin-10, October 29, 2024: no published trial assessed the safety of kisspeptin-10 given chronically or on a fixed schedule for over one day (p. 22); no study reported subcutaneous Cmax or Tmax (p. 18) (opens in a new tab) · Saved copy
- Dosing
Corrected Oct 14, 2026: kisspeptin-10 IV bolus doses in men were 0.01 to 3.0 mcg/kg, with the largest LH rise at 1 mcg/kg, per PubMed (PMID 21632807).
What this does not mean: The dose tiers on this page are unchanged. These were IV boluses dosed per kilogram in healthy men, not subcutaneous community doses.
Source: J Clin Endocrinol Metab 2011, Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Safety
Corrected Oct 14, 2026: kisspeptin-10's side effects now cite its FDA 503A Category 2 listing since Sep 29, 2023, per FDA.
Before: FDA Pharmacy Compounding Advisory Committee rejected kisspeptin for compounding in October 2024; tachyphylaxis study described as daily kisspeptin-54 After: In FDA 503A Category 2 since Sep 29, 2023 (FDA Category 2 page captured Oct 6, 2026); tachyphylaxis study described as twice-daily kisspeptin-54 injections
What this does not mean: No new safety finding. FDA's advisory committee voted 0 to 11 against kisspeptin-10 on Oct 29, 2024, but FDA has not ruled on the 503A bulks list. The cited study used twice-daily kisspeptin-54.
Source: FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2 page, captured Oct 6, 2026) (opens in a new tab) · Saved copy
- Evidence
In healthy men, daily 8-hour kisspeptin-10 infusions kept LH up for 12 days; continuous infusion faded by day 5, per Eur J Endocrinol, Aug 4, 2026.
Before: Desensitization evidence came only from daily kisspeptin-54 in women with hypothalamic amenorrhea (PMID 19820030). After: Adds kisspeptin-10 data in healthy men: continuous infusion lost the LH and FSH rise by day 5; 8 hours on, 16 off kept LH raised for 12 days (PMID 42549827).
What this does not mean: The study used subcutaneous pump infusions in 15 men, not daily injections, so it does not test community injection doses. The dose tiers on this page are unchanged.
Source: European Journal of Endocrinology 2026, chronic subcutaneous kisspeptin-10 in healthy men (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
Peptide Schedule Research TeamReviewed Apr 7, 202611 Citations
References
- [1]Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men (J Clin Endocrinol Metab 2011) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]The effects of kisspeptin-10 on reproductive hormone release show sexual dimorphism in humans (J Clin Endocrinol Metab 2011) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Exploring the pathophysiology of hypogonadism in men with type 2 diabetes: kisspeptin-10 stimulates serum testosterone and LH secretion in men with type 2 diabetes and mild biochemical hypogonadism (Clin Endocrinol 2013) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Subcutaneous injection of kisspeptin-54 acutely stimulates gonadotropin secretion in women with hypothalamic amenorrhea, but chronic administration causes tachyphylaxis (J Clin Endocrinol Metab 2009) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of OHSS during IVF therapy (J Clin Endocrinol Metab 2015) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men (Yeung et al., Eur J Endocrinol 2026) (opens in a new tab)PubMed (opens in a new tab)Clinical Trial
- [7]Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans (kisspeptin-54; EBioMedicine 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- The kisspeptin-GnRH pathway in human reproductive health and disease (Hum Reprod Update 2014) (opens in a new tab)PubMed 24615662PubMed
- Kisspeptin and the hypothalamic control of reproduction: lessons from the human (Endocrinology 2012) (opens in a new tab)PubMed 23015291PubMed
- The KiNG of reproduction: kisspeptin/nNOS interactions shaping hypothalamic GnRH release (Mol Cell Endocrinol 2021) (opens in a new tab)PubMed 33964320PubMed
- FDA: Evaluation of kisspeptin-10, Pharmacy Compounding Advisory Committee briefing (October 29, 2024) (opens in a new tab)Review
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Kisspeptin-10?
Emerging. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: Low. Community mentions on Reddit: Low: sparse vs. BPC-157/TB-500.
792 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
Low search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.